Why UniQure Stock Is Trading Down Today - uniQure (NASDAQ:QURE)

UniQure N.V. (NASDAQ:QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease.

What To Know: The interim data included up to 24 months of follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease.

UniQure will advance the clinical development of AMT-130 through a series of steps, with anticipation of holding regulatory interactions to discuss data from the U.S. and EU studies and the pathway for further advancing the clinical development of AMT-130 by the first quarter of 2024.

HC Wainwright & Co. analyst Patrick Trucchio reiterated uniQure with a Buy and maintained $90 price target.

QURE Price Action: Shares of QURE were down 38.1% at $12.03 at the time of publication, according to Benzinga Pro.

Image by Ewa Urban from Pixabay

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

UniQure N.V. (NASDAQ:QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease.

What To Know: The interim data included up to 24 months of follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease.

"We are very pleased with the data from the interim analysis of our U.S. Phase I/II clinical trial of AMT-130, a one-time administered investigational gene therapy for Huntington's Disease," stated Ricardo Dolmetsch, president of research and development at uniQure. "AMT-130 continues to be generally well-tolerated with a manageable safety profile at both doses. Importantly, both doses show preliminary evidence of clinical and functional benefits, including favorable trends in Total Motor Score, Total Functional Capacity and the composite Unified Huntington's Disease Rating Scale compared to natural history. We plan to engage with regulators to advance this promising clinical program as we collect more data from these patients and from our European study."

HC Wainwright & Co. analyst Patrick Trucchio reiterated uniQure with a Buy and maintained $90 price target.

QURE Price Action: Shares of QURE were down 38.1% at $12.03 at the time of publication, according to Benzinga Pro.

Image by Ewa Urban from Pixabay

QUREuniQure NV

$20.550.24%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.